Novo Nordisk, Bluebird Targeting ‘Lifelong’ Gene Therapies

Duo Hopes To Leapfrog Gene Editing Hemophilia Rivals

 
• By Sten Stovall

Novo Nordisk and bluebird bio will jointly develop genome editing treatments for genetic diseases, beginning with hemophilia.

Edit_Gene
Pact will use bluebird’s gene editing platform based on its megaTAL technology • Source: Shutterstock

More from Business

More from Scrip